Hirudin rDNA Sanofi - Biotech, Pharma and Life Science Channel
PubMed Articles
Longidorus aetnaeus Roca, Lamberti, Agostinelli & Vinciguerra, 1986 is reported for the first time from Iran and Ajaria (Georgia). Morphological and morphometric data are provided for two Iranian and...
A population of Xiphinema macroacanthum Lamberti, Roca & Agostinelli, 1989 originating from olive orchards in Brindisi, Italy and containing both adults and all juvenile stages, is described and illus...
Dupilumab in Persistent Asthma with Elevated Eosinophil Levels.
Background Moderate-to-severe asthma remains poorly treated. We evaluated the efficacy and safety of dupilumab (SAR231893/REGN668), a fully human monoclonal antibody to the alpha subunit of the interl...
Although larvae of the genus Trichinella are the most common parasite species detected in vertebrate muscles using artificial digestion, nematode larvae belonging to other genera are sometimes detecte...
Genus Sphingomonas has received increasing attentions due to its somewhat unique metabolic versatilities in the contaminated environment. However, due to the lack of genus-specific primers, the ecolog...
Nitrate is the second largest contaminant of agriculture soil after pesticides. It also is a major pollutant from nuclear and metallurgical operations. Conventional methods for nitrate removal suffers...
Plant protection through siderophore producing rhizobacteria (SPR) has emerged as a sustainable approach for crop health management. In present study, 220 bacteria isolated from tomato rhizosphere wer...
The seasonal and spatial diversity of picocyanobacteria (Pcy) in lakes of the Great Mazurian Lakes (GLM) system was examined by DGGE analysis of molecular markers derived from the 16S–23S intern...
OBJECTIVE: Aflibercept (Zaltrap(®)) is a novel antiangiogenic agent that binds to vascular endothelial growth factor (VEGF) and inhibits VEGF-dependent tumor growth. We aimed to characterize the popu...
BACKGROUND AND OBJECTIVE: There is a paucity of data in relation to the possible emergence of triclosan (TCS)-resistant bacteria following long-term exposure to TCS toothpaste. Therefore, this study i...
News Articles
Nichi-Iko Japan President: Joint Infliximab Phase III Trials With Sanofi In June 2013
Nichi-Iko Japan President Yuichi Tamura revealed that the company plans to start Phase III trials with the anti-rheumatic drug infliximab (Remicade) biosimilar in collaboration with Sanofi from June.
NPS Pharmaceuticals to Present at Deutsche Bank Health Care Conference
NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) will present at the Deutsche Bank Securities 38th Annual Health Care Conference in Boston on Wednesday, May 29, 2013 at 8:00 a.m. ET. The...
Study: New Drug May Help Some Asthmatics
A new asthma drug being developed by Sanofi and Regeneron Pharmaceuticals may help patients whose condition is not well controlled by existing medicines, according to the results of a small clinical t...
Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
French drug major Sanofi (Euronext: SAN) and US biotech partner Regeneron Pharmaceuticals (Nasdaq: REGN) announced that the New England Journal of Medicine published on-line the positive Phase IIa stu...
Much excitement over Sanofi/Regeneron asthma drug
Much excitement over Sanofi/Regeneron asthma drug
Sanofi, Regeneron announce positive Phase 2a study results of asthma drug
Sanofi and Regeneron Pharmaceuticals have announced positive Phase 2a study results of dupilumab (SAR231893/REGN668) in patients with moderate-to-severe allergic asthma.
UPDATE 1-Regeneron, Sanofi asthma drug seen as potential game changer
May 21 (Reuters) - A new type of asthma drug meant to attack the underlying causes of the respiratory disease slashed episodes by 87 percent in a mid-stage trial, making it a potential game changer fo...
Dupilumab meets in Phase IIa asthma trial
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and partner Sanofi (Euronext:SAN; NYSE:SNY) said once-weekly subcutaneous dupilumab met the primary endpoint of reducing the proportion of patients who exp...
Phase 2 trials show Sanofi, Regeneron drug reduces risk of asthma attacks by 87%
Postive phase 2 clinical trial data of Sanofi and Regeneron's asthma treatment, dupilumab, have today been published in the New England Journal of Medicine. The study found that dupilumab (Sis AR23189...
Sanofi, Regeneron asthma drug seen as breakthrough
Sanofi and Regeneron Pharmaceuticals’ experimental drug, dupilumab, helped hard-to-treat asthma patients in a study, signaling a potential breakthrough therapy for people with persistent cases...
Companies
Zalicus focuses its internal drug development efforts on pain and immuno-inflammatory diseases. Our pipeline for pain includes Exalgo⢠(hydromorphone HCl) extended-release ta...
Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Pa...
Genzyme has pioneered the development and delivery of transformative therapies for patients affected by rare and debilitating diseases for over 30 years. We accomplish our goals t...
Bionest Partners Inc. provides strategy consulting services exclusively for the life science industries to help pharmaceutical, biopharmaceutical, diagnostics, biotechnology, and...
Phase Forward is a leading provider of integrated data management solutions for clinical trials and drug safety. Phase Forwardâs products and services have been utilized in o...
Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other s...
GENFIT (Paris:ALGFT) is a biopharmaceutical company focused on the Discovery and Development of drug candidates in strategic therapeutic fields linked to cardiometabolic and neuro...
Phase Forward is a leading provider of integrated data management solutions for clinical trials and drug safety. Phase Forward's products and services have been utilized in over 1...
EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, is a leader in the US biopharmaceutical arena, integrating cutting-edge science with unparalleled patient support...
EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, is a leader in the US biopharmaceutical arena, integrating cutting-edge science with unparalleled patient support...
Clinical Trials
Open-Label Study of H5 Vaccine in Participants of Protocol 04-077
This study may provide safety information on a flu vaccine given to children and may provide immunogenicity information to add to what was collected in a previous flu vaccine study. Partic...
Immunogenicity and Safety of Tetraxim Versus Local DTP + IPV
The present clinical study will assess the immunogenicity and reactogenicity of Sanofi Pasteur's DTaP-IPV combined vaccines as a three-dose primary vaccination at 2, 4 and 6 months of age...
Assessment of Cardioversion Using Transesophageal Echocardiography II (ACUTE II)
SPECIFIC AIM: To test the safety and feasibility of using low molecular weight heparin (LMWH, enoxaparin sodium; Lovenox, Sanofi-Aventis) in lieu of unfractionated heparin (UFH) as antith...
Revaccination With Subunit Influenza A/Vietnam/1203/2004 (H5N1) Vaccine
The purpose of this study is to determine whether having received an H5 vaccine in the past primes the immune system to respond rapidly to another dose of H5 vaccine. One hundred seventeen...
Somatropin Treatment in Patients With SHOX Deficiency and Turner Syndrome
This clinical trial will compare the mean first year height velocity of somatropin-treated prepubertal patients with SHOX deficiency with the height velocity of a control group of untreate...
Treatment of Abnormal Adipose Tissue Accumulation in HIV Patients
The primary objective of the study is to determine if Serostim® 4 mg administered daily for 12 weeks as treatment for the abnormal fat accumulation and distribution associated with HIV-as...
The study will look at the safety profile (unwanted effects) of the long-lasting anticoagulant PEG-hirudin (SPP200) and compare these unwanted effects to those of unfractionated heparin, c...
The purpose of the study is to compare the effect in blood sugar control between Lantus and twice daily intermediate acting insulins (NPH or Lente) when used as the basal insulin in a mult...
The purposes of the study is to determine whether blood sugar control is different between Lantus and a third oral anti-diabetic agent when added to patients who fail a thiazolidinedione a...
Vaccine for Prevention of Bird Flu
Study Design: This is a Phase I, randomized, open-label study to evaluate the safety, tolerability, and immunogenicity of four vaccination regimens against the influenza virus hemagglutin...
Videos
Medical and Biotech [MESH] Definitions
Actinobacteria
Class of BACTERIA with diverse morphological properties. Strains of Actinobacteria show greater than 80% 16S rDNA/rRNA sequence similarity among each other and also the presence of certain signature nucleotides. (Stackebrandt E. et al, Int. J. Syst. Bacteriol. (1997) 47:479-491)
Dna, Ribosomal Spacer
The intergenic DNA segments that are between the ribosomal RNA genes (internal transcribed spacers) and between the tandemly repeated units of rDNA (external transcribed spacers and nontranscribed spacers).
Hirudin Therapy
Use of HIRUDINS as an anticoagulant in the treatment of cardiological and hematological disorders.
